SNY — Sanofi
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1121404 ·
Last close
$41.60
Market Cap
$99.58B
52W High
$46.05
52W Low
$40.89
ADV30
3,215,946
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 11,244,000,000 | 8,106,000,000 | 2,269,000,000 | 1,614,000,000 | 128,024,000,000 | 5,544,000,000 | 54,881,000,000 |
| Dec 2025 | 12,205,000,000 | 8,449,000,000 | 1,630,000,000 | -801,000,000 | 126,805,000,000 | 7,657,000,000 | 55,095,000,000 |
| Sep 2025 | 13,170,000,000 | 9,758,000,000 | 3,785,000,000 | 2,802,000,000 | 129,794,000,000 | 8,906,000,000 | 56,261,000,000 |
| Jun 2025 | 10,735,000,000 | 7,743,000,000 | 1,712,000,000 | 3,940,000,000 | 124,959,000,000 | 15,359,000,000 | 54,680,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$10,336,000,000
Investing CF
$-14,175,000,000
Financing CF
$-9,102,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
$23,503,000,000
Receivables
$482,000,000
ST Investments
—
EBIT TTM
$6,550,000,000
Pretax Income TTM
$6,020,000,000
Interest Exp TTM
$530,000,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$47,353,999,360
EBITDA
$12,826,999,808
Free Cash Flow
$16,672,499,712
Enterprise Value
$115,001,442,304
Total Cash
$5,544,000,000
Total Debt
$20,021,000,192
Shares Out
2,393,769,026
Trailing EPS
$2.27
Book Value
$34.68
ROE
6.6%
ROA
4.7%
Div Yield
5.81%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,716,000,000 | 9,597,000,000 | 7,813,000,000 | 126,805,000,000 | 55,095,000,000 | — | 10,750,000,000 |
| Dec 2024 | 44,286,000,000 | 8,923,000,000 | 5,560,000,000 | 132,798,000,000 | 54,941,000,000 | — | 9,081,000,000 |
| Dec 2023 | 41,618,000,000 | 8,691,000,000 | 5,400,000,000 | 126,464,000,000 | 52,111,000,000 | — | 10,258,000,000 |
| Dec 2022 | 40,561,000,000 | 10,926,000,000 | 8,371,000,000 | 126,722,000,000 | 51,570,000,000 | — | 10,526,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$5.29
Max Pain — expiry 2026-07-17
max pain strike: $42.50 · spot: $41.68 · call oi: 6,755 · put oi: 2,250
Expected Move to 2026-07-17:
±$2.03
(4.86%) —
implied range
$39.66 –
$43.71
· ATM straddle on $42.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNYNF | Sanofi | $99.81B | $83.39 | — |
| GLAXF | GSK plc | $102.97B | $25.70 | — |
| GSK | GSK plc | $104.31B | $52.07 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $113.40B | $55.53 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $118.89B | $468.42 | — |
News headlines (Yahoo Finance, 1h cache)
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
How Back‑to‑Back BTK Drug Approvals At Sanofi (ENXTPA:SAN) Has Changed Its Investment Story
2026-06-24 12:10 · Yahoo
Sanofi (ENXTPA:SAN) Wins Two Drug Approvals In Japan And The EU
2026-06-24 11:12 · Yahoo
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
2026-06-24 08:12 · Yahoo
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
2026-06-23 15:24 · Yahoo
How Kardigan spun deal leftovers into a $400M IPO
2026-06-23 10:21 · Yahoo
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
2026-06-23 05:15 · Yahoo
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
2026-06-23 05:00 · Yahoo
DoH and Sanofi Partner to Advance Vaccine Innovation
2026-06-22 23:46 · Yahoo
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-06-22 20:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.